Regulatory EMA seeks input on virtual alternative to animal test PharmaphorumEMA delivers a milestone in the replacement of animals in drug testing with the qualification of a virtual model for repeat-dose toxicity studies.RegulatoryRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaphorum EMA delivers a milestone in the replacement of animals in drug testing with the qualification of a virtual model for repeat-dose toxicity studies. RegulatoryRead full story Post navigation Previous: Novo Sheds 400 at Embattled Manufacturing SiteNext: IO Shuts Down Following Regulatory Roadblocks Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
